Evidence map›Paper›PMID 37822075›Full record

ArticleBritish journal of haematology2024

Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.

Omar Mamlouk, Paolo Strati, Lei Feng, Ryan Sun, Amy Ayers, Raphael E Steiner, Ranjit Nair, Christopher Flowers, Jeremy L Ramdial, Neeraj Saini and 11 more

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Omar MamloukSection of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1242-2740
Paolo StratiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7445-1459
Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ryan SunDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Amy AyersDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Raphael E SteinerDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-3717-3629
Ranjit NairDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christopher FlowersDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeremy L RamdialDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-8984-3420
Neeraj SainiDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Samer A SrourDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6693-2025
Richard E ChamplinDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Partow KebriaeiDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Loretta J NastoupilDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maria A RodriguezDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth J ShpallDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yago NietoDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-6034-8939
Jason WestinDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sattva S NeelapuDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sreedhar MandayamSection of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sairah AhmedDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7302-8299
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunotherapy, AdoptiveLymphomaAntigens, CD19HumansKidneyT-LymphocytesAntigens, CD19

Identifiers

PMID37822075
PMCPMC12489800
OpenAlexW4387564236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.